Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 34

Sort by

Sort Order Select

Journal Articles

CD30.CAR-T Cells Co-Expressing the CCR4 Chemokine Receptor in Relapsed/Refractory Hodgkin Lymphoma

Natalie Grover, Dominic Moore, Anastasia Ivanova, Anne W Beaven, Christopher Dittus, Catherine Joyce Arago Cheng, Kelly Hoye, Caroline Babinec, Faith Brianne Buchanan, Angela Denise Spruill, Ashley Zanter, John West, J. Kaitlin Morrison, Paul Armistead, Kimberly A. Kasow, Jonathan Serody, Gianpietro Dotti, Barbara Savoldo

Blood (2024) 144 (Supplement 1): 919.

https://doi.org/10.1182/blood-2024-200932

Published: 2024

Journal Articles

Phase 1 Trial of CD30-Directed, CCR4 Co-Expressing Chimeric Antigen Receptor T-Cells in Patients with CD30 + Cutaneous T-Cell Lymphomas Refractory to Brentuximab Vedotin

Daniel K Reef, Catherine Joyce Arago Cheng, Caroline Babinec, Kelly Hoye, John West, J. Kaitlin Morrison, Faith Brianne Buchanan, Ashley Zanter, Angela Denise Spruill, Kimberly A. Kasow, Anastasia Ivanova, Edith Bowers, Jonathan Serody, Barbara Savoldo, Gianpietro Dotti, Natalie Grover, Anne W Beaven

Blood (2024) 144 (Supplement 1): 3468.

https://doi.org/10.1182/blood-2024-201799

Published: 2024

Journal Articles

Donor Hemoglobin Genotype Does Not Impact Outcomes Following Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Study

Elizabeth Stenger, Tami D. John, Deepak Chellapandian, Rikin Shah, Scott Gillespie, Yijin Xiang, Katie Liu, Monica Bhatia, Gregory M.T. Guilcher, Jennifer Jaroscak, Kimberly A. Kasow, Jennifer Krajewski, Alexander I. Ngwube, Hemalatha G. Rangarajan, John T. Horan, Lakshmanan Krishnamurti, Shalini Shenoy, Allistair Abraham

Blood (2023) 142 (Supplement 1): 4955.

https://doi.org/10.1182/blood-2023-188514

Published: 2023

Journal Articles

Regimen Intensity and Age Affect Transplant-Related Outcomes after Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Registry Study

Blood (2023) 142 (Supplement 1): 4904.

https://doi.org/10.1182/blood-2023-182532

Published: 2023

Journal Articles

Efficacy, Safety, and Health-Related Quality of Life (HRQOL) in Patients with Sickle Cell Disease (SCD) Who Have Received Lovotibeglogene Autotemcel (Lovo-cel) Gene Therapy: Up to 60 Months of Follow-up

Julie Kanter, Alexis A. Thompson, Janet L. Kwiatkowski, Suhag Parikh, Markus Mapara, Stacey Rifkin-Zenenberg, Banu Aygun, Kimberly A. Kasow, Ashish O. Gupta, Lixin Zhang, Emily Sheldon-Waniga, Meghan Gallagher, Katiana Gruppioni, Anjulika Chawla, Heidi Elliot, Francis J. Pierciey, Mark C. Walters, John F. Tisdale

Blood (2023) 142 (Supplement 1): 1051.

https://doi.org/10.1182/blood-2023-174229

Published: 2023

Journal Articles

Lovo-cel (bb1111) Gene Therapy for Sickle Cell Disease: Updated Clinical Results and Investigations into Two Cases of Anemia from Group C of the Phase 1/2 HGB-206 Study

Mark C. Walters, Alexis A. Thompson, Janet L. Kwiatkowski, Suhag Parikh, Markus Y. Mapara, Stacey Rifkin-Zenenberg, Banu Aygun, Kimberly A. Kasow, Alex Miller, Lixin Zhang, Anjulika Chawla, Elizabeth R. Macari, Francis J. Pierciey, Jr., John F. Tisdale, Julie Kanter

Blood (2022) 140 (Supplement 1): 26–28.

https://doi.org/10.1182/blood-2022-162288

Published: 2022

Journal Articles

Metabolomic identification of α-ketoglutaric acid elevation in pediatric chronic graft-versus-host disease

Blood (2022) 139 (2): 287–299.

https://doi.org/10.1182/blood.2021013244

Published: 2022

Includes: Supplemental data

Journal Articles

Long-Term Quality of Life after Hematopoietic Cell Transplantation for Sickle Cell Disease: A Preliminary Report from the Sickle Cell Transplant Evaluation of Long Term and Late Effects Registry (STELLAR)

Staci D. Arnold, Nitya Bakshi, Zhao Chang, Diana Ross, Allistair Abraham, Monica Bhatia, Gregory M.T. Guilcher, Ann Haight, Matthew Hsieh, Kimberly A. Kasow, Peter A. Lane, Lillian Meacham, Festus Olusola Olowoselu, Lakshmanan Krishnamurti

Blood (2021) 138 (Supplement 1): 425.

https://doi.org/10.1182/blood-2021-154280

Published: 2021

Journal Articles

Polyclonality Strongly Correlates with Biological Outcomes and Is Significantly Increased Following Improvements to the Phase 1/2 HGB-206 Protocol and Manufacturing of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy (GT)

Blood (2021) 138 (Supplement 1): 561.

https://doi.org/10.1182/blood-2021-147760

Published: 2021

Journal Articles

CD30-Directed Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Hodgkin Lymphoma and Non-Hodgkin Lymphoma in Pediatric Patients

George E. Hucks, Jr., Barbara Savoldo, Gianpietro Dotti, Catherine Joyce Arago Cheng, Caroline Babinec, Kimberly A. Kasow, Michael Winstead, Arpita Patel, Cammie Presler, Natalie S Grover, J. Kaitlin Morrison, Anne W. Beaven, Marcie L. Riches, Thomas C. Shea, Jonathan S. Serody

Blood (2021) 138 (Supplement 1): 2829.

https://doi.org/10.1182/blood-2021-153968

Published: 2021

Journal Articles

Mobility and Muscle Strength in Recipients of Hematopoietic Cell Transplantation for Sickle Cell Disease: A Preliminary Report from Sickle Transplant Evaluation of Longterm and Late Effects Registry (STELLaR)

Anirudh Veludhandi, Tami D John, Nitya Bakshi, Staci D. Arnold, Monica Bhatia, Peter A. Lane, Lillian Meacham, Kirshma Khemani, Sonali Chaudhury, Festus Olusola Olowoselu, Kimberly A. Kasow, Matthew Hsieh, Allistair Abraham, Gregory M.T. Guilcher, Lakshmanan Krishnamurti

Blood (2021) 138 (Supplement 1): 3030.

https://doi.org/10.1182/blood-2021-152383

Published: 2021

Journal Articles

Sustained Improvements in Patient-Reported Quality of Life up to 24 Months Post-Treatment with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Mark C. Walters, John F. Tisdale, Markus Y. Mapara, Lakshmanan Krishnamurti, Janet L. Kwiatkowski, Banu Aygun, Kimberly A. Kasow, Stacey Rifkin-Zenenberg, Jennifer Jaroscak, Diana Garbinsky, Costel Chirila, Meghan E. Gallagher, Xinyan Zhang, Pei-Ran Ho, Alexis A. Thompson, Julie Kanter

Blood (2021) 138 (Supplement 1): 7.

https://doi.org/10.1182/blood-2021-146905

Published: 2021

Journal Articles

Naïve Helper T-Cell and Regulatory T- and NK-Cell Subsets Are Associated with Pediatric Chronic Graft-Versus-Host Disease: Results of the ABLE / PBMTC 1202 Study

Blood (2020) 136 (Supplement 1): 11–12.

https://doi.org/10.1182/blood-2020-139031

Published: 2020

Journal Articles

Resolution of Serious Vaso-Occlusive Pain Crises and Reduction in Patient-Reported Pain Intensity: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Alexis A. Thompson, MD, Mark C. Walters, MD, Markus Y Mapara, MD PhD, Janet L. Kwiatkowski, MD MSCE, Lakshmanan Krishnamurti, MD, Banu Aygun, MD, Kimberly A. Kasow, DO, Stacey Rifkin-Zenenberg, DO, Manfred Schmidt, PhD, Jay DelCarpini, Francis J. Pierciey, Jr., Alexandra L. Miller, Meghan E. Gallagher, MSc, Ren Chen, Sunita Goyal, MD, Julie Kanter, MD, John F. Tisdale, MD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-134940

Published: 2020

Journal Articles

Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies

Blood (2020) 135 (15): 1287–1298.

https://doi.org/10.1182/blood.2019003186

Published: 2020

Includes: Supplemental data

Journal Articles

Pediatric Hematologist/Oncologists' Beliefs about Hematopoietic Stem Cell Transplant for Children with Sickle Cell Disease: A Sickle Cell Transplant Advocacy and Research Alliance (STAR) Study

Emily Riehm Meier, MD MSHS, Allistair Abraham, MD, Alexander I. Ngwube, MD, Isaac Janson, PhD, Gregory M.T. Guilcher, MD, John T. Horan, MDMPH, Kimberly A. Kasow, DO

Blood (2019) 134 (Supplement_1): 2164.

https://doi.org/10.1182/blood-2019-130543

Published: 2019

Journal Articles

Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria

Blood (2019) 134 (3): 304–316.

https://doi.org/10.1182/blood.2019000216

Published: 2019

Includes: Supplemental data

Journal Articles

Related and Unrelated Donor Transplantation for β Thalassemia Major: Results of an International Survey

Blood (2018) 132 (Supplement 1): 308.

https://doi.org/10.1182/blood-2018-99-111152

Published: 2018

Journal Articles

Similar Event-Free Survival but Higher Incidence of Mixed T Cell Chimerism after Hematopoietic Cell Transplantation for Sickle Cell Disease Using Rabbit Versus Horse ATG: a Study from the Sickle Transplant Alliance for Research (STAR)

Allistair Abraham, MD, Elizabeth Stenger, MD, Curtis D Travers, MPH, Robert Nickel, MDMSc, Hemalatha G. Rangarajan, MD, Jennifer Krajewski, MD, Sonali Chaudhury, MBBS,MD, Kimberly A. Kasow, DO, Troy C. Quigg, DO, Alexander I. Ngwube, MD, Jennifer Jaroscak, MD, Gregory M Guilcher, MDBSc,FRCPC, Shalini Shenoy, MD, John T Horan, MD

Blood (2017) 130 (Supplement 1): 3535.

https://doi.org/10.1182/blood.V130.Suppl_1.3535.3535

Published: 2017

Journal Articles

Development of a Multi-Center Cohort to Evaluate Long-Term Outcomes and Late Effects Following Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Initiative

Elizabeth Stenger, MD, Allistair Abraham, MD, Curtis D Travers, MPH, Hemalatha G. Rangarajan, MD, Diane Hsu, MD, Sonali Chaudhury, MBBS,MD, Kimberly A. Kasow, DO, Michael J. Eckrich, MD MPH, Alexander I. Ngwube, MD, Julie Kanter, MD, Gregory M Guilcher, MDBSc,FRCPC, John T. Horan, MDMPH, Lakshmanan Krishnamurti, MD, Shalini Shenoy, MD

Blood (2017) 130 (Supplement 1): 3271.

https://doi.org/10.1182/blood.V130.Suppl_1.3271.3271

Published: 2017

NARROW

CD30.CAR-T Cells Co-Expressing the CCR4 Chemokine Receptor in Relapsed/Refractory Hodgkin Lymphoma

Phase 1 Trial of CD30-Directed, CCR4 Co-Expressing Chimeric Antigen Receptor T-Cells in Patients with CD30 + Cutaneous T-Cell Lymphomas Refractory to Brentuximab Vedotin

Donor Hemoglobin Genotype Does Not Impact Outcomes Following Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Study

Regimen Intensity and Age Affect Transplant-Related Outcomes after Matched Related Donor Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Registry Study

Efficacy, Safety, and Health-Related Quality of Life (HRQOL) in Patients with Sickle Cell Disease (SCD) Who Have Received Lovotibeglogene Autotemcel (Lovo-cel) Gene Therapy: Up to 60 Months of Follow-up

Lovo-cel (bb1111) Gene Therapy for Sickle Cell Disease: Updated Clinical Results and Investigations into Two Cases of Anemia from Group C of the Phase 1/2 HGB-206 Study

Metabolomic identification of α-ketoglutaric acid elevation in pediatric chronic graft-versus-host disease

Long-Term Quality of Life after Hematopoietic Cell Transplantation for Sickle Cell Disease: A Preliminary Report from the Sickle Cell Transplant Evaluation of Long Term and Late Effects Registry (STELLAR)

Polyclonality Strongly Correlates with Biological Outcomes and Is Significantly Increased Following Improvements to the Phase 1/2 HGB-206 Protocol and Manufacturing of LentiGlobin for Sickle Cell Disease (SCD; bb1111) Gene Therapy (GT)

CD30-Directed Chimeric Antigen Receptor (CAR)-T Cells for Treatment of Hodgkin Lymphoma and Non-Hodgkin Lymphoma in Pediatric Patients

Mobility and Muscle Strength in Recipients of Hematopoietic Cell Transplantation for Sickle Cell Disease: A Preliminary Report from Sickle Transplant Evaluation of Longterm and Late Effects Registry (STELLaR)

Sustained Improvements in Patient-Reported Quality of Life up to 24 Months Post-Treatment with LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Naïve Helper T-Cell and Regulatory T- and NK-Cell Subsets Are Associated with Pediatric Chronic Graft-Versus-Host Disease: Results of the ABLE / PBMTC 1202 Study

Resolution of Serious Vaso-Occlusive Pain Crises and Reduction in Patient-Reported Pain Intensity: Results from the Ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin for Sickle Cell Disease (bb1111) Gene Therapy

Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies

Pediatric Hematologist/Oncologists' Beliefs about Hematopoietic Stem Cell Transplant for Children with Sickle Cell Disease: A Sickle Cell Transplant Advocacy and Research Alliance (STAR) Study

Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria

Related and Unrelated Donor Transplantation for β Thalassemia Major: Results of an International Survey

Similar Event-Free Survival but Higher Incidence of Mixed T Cell Chimerism after Hematopoietic Cell Transplantation for Sickle Cell Disease Using Rabbit Versus Horse ATG: a Study from the Sickle Transplant Alliance for Research (STAR)

Development of a Multi-Center Cohort to Evaluate Long-Term Outcomes and Late Effects Following Hematopoietic Cell Transplantation for Sickle Cell Disease: A STAR Initiative

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only